About Us
Company Overview
Vision / Mission / Values
Leadership
Clinical Advisory Board
Partnering
Our Approach
Technologies
Manufacturing
Publications
Pipeline
Pipeline
Autologous CAR-T
Allogeneic CAR-T
Expanded Access
Investors
Announcements
Corporate Governance
Corporate Deck & Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Newsroom
Careers
Join Us
Contact Us
EN
简
About Us
Company Overview
Vision / Mission / Values
Leadership
Clinical Advisory Board
Partnering
Our Approach
Technologies
Manufacturing
Publications
Pipeline
Pipeline
Autologous CAR-T
Allogeneic CAR-T
Expanded Access
Investors
Announcements
Corporate Governance
Corporate Deck & Presentations
Webcasts
Presentations
Financial Reports
Listing Documents
IR Contact
Newsroom
Careers
Join Us
Contact Us
Newsroom
Home
-
Newsroom
-
Search News
23
Sep 2019
CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency
Sep 23, 2019
31
Aug 2019
CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma
Aug 31, 2019
19
Jun 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR T cells from the U.S. FDA
Jun 19, 2019
01
Mar 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR T cells from the NMPA
Mar 01, 2019
29
Jan 2019
CARsgen Therapeutics Receives IND Clearance for GPC3-CAR T cells from the NMPA
Jan 29, 2019
04
Dec 2018
CARsgen Presents Preliminary Results of CAR-BCMA T Cell Therapy at ASH 2018
Dec 04, 2018
27
Aug 2018
CARsgen Appoints Dr. Hong MA as Senior Vice President of Clinical Development
Aug 27, 2018
02
Mar 2018
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
Mar 02, 2018
10
Aug 2017
CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial
Aug 10, 2017
30
Jun 2017
CARsgen Therapeutics Joins The Alliance for Regenerative Medicine
Jun 30, 2017
1
...
8
9
10